The DOI matches its Crossref record; 83 of the 84 references it cites were found in a registry or an index; 46 of the 104 sources its claims cite were checked for support.
The progression of secondary diabetes: A review of modeling studies
Open accessAbstract
Mathematical modeling has provided quantitative information consistent with experimental data, greatly improving our understanding of the progression of type 1 and type 2 diabetes. However, diabetes is a complex metabolic disease and has been found to be involved in crosstalk interactions with diverse endocrine diseases. Mathematical models have also been developed to investigate the quantitative impact of various hormonal disorders on glucose imbalance, advancing the precision treatment for secondary diabetes. Here we review the models established for the study of dysglycemia induced by hormonal disorders, such as excessive glucocorticoids, epinephrine, and growth hormone. To investigate the influence of hyperthyroidism on the glucose regulatory system, we also propose a hyperthyroid-diabetes progression model. Model simulations indicate that timely thyroid treatment can halt the progression of hyperglycemia and prevent beta-cell failure. This highlights the diagnosis of hormonal disorders, together withblood sugar tests, as significant measures for the early diagnosis and treatment of diabetes. The work recapitulates updated biological research on the interactions between the glucose regulatory system and other endocrine axes. Further mathematical modeling of secondary diabetes is desired to promote the quantitative study of the disease and the development of individualized diabetic therapies.
Overview
CoChat Summary
TL;DR
This review summarizes mathematical models of secondary diabetes caused by excess glucocorticoids, epinephrine, and growth hormone, and proposes a new hyperthyroid-diabetes progression model. Simulations suggest timely anti-thyroid treatment can halt hyperglycemia and prevent beta-cell failure, whereas delayed treatment does not reverse diabetes.
Key findings
- The paper reviews existing models for dysglycemia induced by glucocorticoids, epinephrine, and growth hormone, noting that models for secondary diabetes remain sparse compared with type 1 and type 2 diabetes models.
- In the new hyperthyroid-diabetes model, a fast-progressing virtual patient’s glucose reached 122.5 mg/dl on day 507, was dragged down to 114.5 mg/dl in 63 days, then crossed the 125 mg/dl diabetes threshold after 1.7 years; complete beta-cell failure occurred when FT4 exceeded its set point by 124%.
- A slowly progressing virtual patient reached FT4 20 pg/ml in about 18.5 years, 17 years later than the fast-progressing patient, and diabetes onset was postponed by 16.7 years; however, at FT4 24.1 pg/ml this patient was in late-stage diabetes while the fast-progressing patient had just crossed the diabetes threshold.
- Timely anti-thyroid drug treatment starting after day 500 reduced FT4 by 5.2 pg/ml and glucose by 19.3 units in 10 days, with FT4 approaching 12.9 pg/ml and glucose regulated within normal range after day 1500; belated treatment starting on day 700 failed to reverse diabetes.
Methods
- Narrative review of mathematical models for secondary diabetes induced by glucocorticoids, epinephrine, and growth hormone, plus formulation of a new hyperthyroid-diabetes progression model based on a previous generalized diabetes progression model.
- The new model incorporates FT4 and TSH dynamics, a hyperthyroid factor \(X=|T3-U|/U\), influence functions \(p_i(X)\), and an anti-thyroid drug treatment term; parameters are listed in Table 1, with several adopted from prior work validated by Pima Indian data.
- Simulations compare virtual patients with fast versus slow hyperthyroid progression and different anti-thyroid drug regimens; normal reference ranges used include FT4 7–18 pg/ml, TSH 0.4–4 mU/l, and FT4 set point \(U=12.5\) pg/mL.
Limitations
- The paper states the hyperthyroid submodel includes only FT4 and TSH, omitting T3–TSH interaction, deiodinase activities, TSH effects on glucose regulation, and effects of excess thyroid hormones on insulin degradation for simplicity.
- The paper states the model was not validated with individual measurements of blood glucose, insulin, FT4, and TSH, calling this a common predicament for models of interacting subsystems.
- Evident from the text: the new model’s conclusions rest on deterministic simulations of virtual patients rather than clinical cohort data, and the authors note stochastic or statistical models would be closer to reality but more complex.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
40 Valid · 1 Not valid · 36 Not checked · 60 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“The lab testof FT4 is considered as a more accurate evaluation of thyroid hormone concentration than the measurement of total T3, T4 and FT3 due to the limitation of measuring technique (67).”
§ The progression of secondary diabetes: A review of modeling studies > Hyperthyroidism-induced diabetes
What the sources say
- Disputedcites [67] Li, 2014, Clinical evaluation of various thyroid hormones on thyroid function, Int J Endocrinol sourceExperimental — accuracy not yet measured
The Discussion says the opposite of the claim's central comparison: because current FT4 measurements lack stability and accuracy, TT4 is better than FT4 for clinical measurement and thyroid-function assessment. It also describes FT4 measurement as indirect and less stable and repeatable than TT4. No page number is provided in our copy. (LLM, conf=0.94)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Every source the paper cites for this claim was checked and supports it.
In the paper
“Moreover, experiments have shown low dose of β 2-adrenoceptor agonists can improve glucose tolerance in diet-induced obese mice within 4 days of treatment.”
§ The progression of secondary diabetes: A review of modeling studies > Existing models of secondary diabetes > Models studying the impact of epinephrine on glucose regulation
What the sources say
- Supportedcites [32] Kalinovich, 2020, Treatment with a β-2-adrenoceptor agonist stimulates glucose uptake in skeletal muscle and improves glucose homeostasis, insulin resistance and hepatic steatosis in mice with diet-induced obesity, Diabetologia source
The Results section, under “Chronic treatment with low-dose clenbuterol does not affect insulin release but improves insulin sensitivity,” reports improved glucose tolerance after four days of low-dose clenbuterol treatment in diet-induced obese mice. Clenbuterol is a β2-adrenoceptor agonist. (LLM, conf=0.95)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Research in murine models and human studies have shown excess GCs can cause compensatory beta-cell hyperplasia and hyperinsulinemia, with the coexistence of normoglycemia.”
§ The progression of secondary diabetes: A review of modeling studies > Existing models of secondary diabetes > A model of hypercortisolism-induced dysglycemia
What the sources say
- Supportedcites [22] Kuo, 2015, Regulation of glucose homeostasis by glucocorticoids, Glucocorticoid Signaling source
The “GC Effects on Pancreas” section directly states that, in murine models and human studies, GC-induced insulin resistance can lead to compensatory β-cell hyperplasia, hyperinsulinemia, and consequent normoglycemia. It also notes that compensation may fail with long-term GC treatment, consistent with the citing sentence’s use of “can.” (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“An elevated risk of T2DM in patients with hyperthyroidism has been documented (6, 7).”
§ The progression of secondary diabetes: A review of modeling studies > Hyperthyroidism-induced diabetes
What the sources say
- Partly supportedcites [6] Brandt, 2013, Morbidity before and after the diagnosis of hyperthyroidism: a nationwide register-based study, PloS One sourceExperimental — accuracy not yet measured
The Results report a significantly higher risk of diabetes mellitus diagnosis after a hyperthyroidism diagnosis. However, the Methods define diabetes mellitus as a combined outcome without separating type 2 from type 1, so the paper does not establish the claim specifically for T2DM. (LLM, conf=0.88)
- Partly supportedcites [7] Wang, 2013, The relationship between type 2 diabetes mellitus and related thyroid diseases, J Diabetes Res sourceExperimental — accuracy not yet measured
Section 4.1 links hyperthyroidism to insulin resistance, and Section 3.1 says thyrotoxicosis can worsen subclinical diabetes and hyperglycaemia in T2DM. Neither passage documents an elevated risk of developing T2DM among patients with hyperthyroidism. (LLM, conf=0.83)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“However, long-term GCs therapy that oversteps the beta-cell compensatory capacity begets impaired insulin secretion, hyperglycemia, and consequent type 2 diabetes (22).”
§ The progression of secondary diabetes: A review of modeling studies > Existing models of secondary diabetes > A model of hypercortisolism-induced dysglycemia
What the sources say
- Supportedcites [22] Kuo, 2015, Regulation of glucose homeostasis by glucocorticoids, Glucocorticoid Signaling source
The “GC Effects on Pancreas” section states that long-term GC treatment exceeding β-cell compensatory capacity leads to insufficient insulin secretion, hyperglycemia, and eventually type 2 diabetes. This directly supports the citing sentence. (LLM, conf=0.95)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
88 more claims · 16 with their cited sources checked
Create a free account to see all 137 claims and to verify the 2 references still open.
- It may state two separate claims as one. 24
- Probably not a substantial claim. 26
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ The progression of secondary diabetes: A review of modeling studies > Hyperthyroidism-induced diabetes > Significance of hyperthyroid treatment for glucose control
“D = 8, for 600< t ≤ 700”
§ The progression of secondary diabetes: A review of modeling studies > Hyperthyroidism-induced diabetes > Significance of hyperthyroid treatment for glucose control
“We then increase the ATD dose to 5 mg for the next 100 days.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The progression of secondary diabetes: A review of modeling studies > Hyperthyroidism-induced diabetes > Significance of hyperthyroid treatment for glucose control
“an increased dosage is applied every one hundred days until day 800 when the dosage becomes fixed.”
§ The progression of secondary diabetes: A review of modeling studies > Hyperthyroidism-induced diabetes > Significance of hyperthyroid treatment for glucose control
“D = 15, for 800< t ≤ 900; D = 20, for t > 900.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The progression of secondary diabetes: A review of modeling studies > Hyperthyroidism-induced diabetes > Influence of hyperthyroidism on the progression of diabetes
“assume U=12.5 pg/mL (the average value of the lower and upper bound of FT4) as the set point of FT4”
§ The progression of secondary diabetes: A review of modeling studies > Hyperthyroidism-induced diabetes > Influence of hyperthyroidism on the progression of diabetes
“| U | 12.5 | mmol·L –1 | see text |”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The progression of secondary diabetes: A review of modeling studies > Hyperthyroidism-induced diabetes > Influence of hyperthyroidism on the progression of diabetes
“The remaining parameters are adopted from our previous work (56) where the model was validated by the Pima Inidan data.”
§ The progression of secondary diabetes: A review of modeling studies > Hyperthyroidism-induced diabetes > Influence of hyperthyroidism on the progression of diabetes
“| d 1 | 0.099 | day –1 | (55) |”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The progression of secondary diabetes: A review of modeling studies > Hyperthyroidism-induced diabetes > Influence of hyperthyroidism on the progression of diabetes
“Graph (b) shows patient B would reach the FT4 level of 20 mg/dl in approximately 18.5 years”
§ The progression of secondary diabetes: A review of modeling studies > Hyperthyroidism-induced diabetes > Influence of hyperthyroidism on the progression of diabetes
“patient B develops hyperthyroidism at a slow rate, spending an extra 17 years more than patient A to reach the FT4 level of 20 pg/ml”
Citations
Cites
Toprak, O., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,627
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011 · cited 1×
“These models were validated by data from the Diabetes Prevention Program study (18, 19), capable of describing the effect of intensive lifestyle intervention and metformin administration, as well as the long-term variation of diagnostic indices in cohorts of virtual patients.”
MethodDiagnosis and classification of diabetes mellitus
American Diabetes Association (2010) · Diabetes Care · doi:10.2337/dc10-s062 · Cited by 5,491
Bergman, R. N., Phillips, L. S., & Cobelli, C. (1981) · Journal of Clinical Investigation · doi:10.1172/jci110398 · Cited by 1,640 · cited 2×
“The model is extended upon the Bergman Minimal Model (44) by adding terms to the glucose equation to account for the influence of epinephrine:”
MethodLaboratory Support for the Diagnosis and Monitoring of Thyroid Disease
(2003) · Thyroid · doi:10.1089/105072503321086962 · Cited by 1,212
Glucose transporters in the 21st Century
Thorens, B., & Mueckler, M. (2010) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00712.2009 · Cited by 1,013 · cited 2×
“In pancreatic beta cells, GLUT1, GLUT2 and GLUT3 are involved in glucose sensing and possess different affinities for extracellular glucose compared to those in fat and muscle cells (26, 28).”
BackgroundStatistical Thermodynamics of Nonequilibrium Processes
Keizer, J. (1987) · Springer eBooks · doi:10.1007/978-1-4612-1054-2 · Cited by 788
Regulation of glucose homeostasis by glucocorticoids
Kuo, T., McQueen, A., Chen, T.-C., & Wang, J.-C. (2015) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4939-2895-8_5 · Cited by 723 · cited 2×
“As a result, over-exposure to GCs leads to hyperglycemia and insulin resistance (22).”
BackgroundThyroid dysfunction and diabetes mellitus: two closely associated disorders
Biondi, B., Kahaly, G. J., & Robertson, R. P. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00163 · Cited by 598 · cited 4×
“Moreover, T3 exerts profound effects on the proliferation of pancreatic islet cells and insulin secretion (57, 59).”
BackgroundInfluentialPrevention of Type 2 Diabetes With Troglitazone in the Diabetes Prevention Program
The Diabetes Prevention Program Research Group* (2005) · Diabetes · doi:10.2337/diabetes.54.4.1150 · Cited by 474 · cited 1×
“These models were validated by data from the Diabetes Prevention Program study (18, 19), capable of describing the effect of intensive lifestyle intervention and metformin administration, as well as the long-term variation of diagnostic indices in cohorts of virtual patients.”
Method
Research works printed but not linked: 4
- Chwalba, 2020, Secondary diabetes, Austin J Nutr Metab, 1077
- Hall, 2010, Guyton and hall textbook of medical physiology e-book
- Ahren, 2003, Beta-cell function and insulin secretion
- Genuth, 1990, Associations between diabetes and other endocrine disorders, Clin Diabetes
Cited by
A simplified longitudinal model for the development of Type 2 Diabetes Mellitus
Gaetano, A. D., Nagy, I., Kiss, D. K., Romanovski, V. G., & Hardy, T. A. (2024) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2024.111822 · Cited by 5
Ramos, M., Gerlier, L. C., Uster, A., Muttram, L., Steubl, D., Frankel, A., & Lamotte, M. (2024) · Renal Failure · doi:10.1080/0886022x.2024.2406402 · Cited by 3
Mathematical Modeling in Diabetes Care and Innovation
Maamar, M. H. (2025) · Industrial and applied mathematics · doi:10.1007/978-981-96-1925-2_4 · Cited by 2
MATHEMATICAL MODEL FOR PREDICTING FASTING BLOOD GLUCOSE LEVEL IN DIABETES MELLITUS PATIENTS
Ziukov, O. L., Оshyvalova, О. О., & Biloshytska, O. K. (2023) · Wiadomości Lekarskie · doi:10.36740/wlek202310125 · Cited by 2
Mathematical Modelling for Glucose Homeostasis and Associated Mechanisms: A State-of-the-Art Review
Lamlili, M. E. N., Boutayeb, W., & Boutayeb, A. (2025) · Industrial and applied mathematics · doi:10.1007/978-981-96-1925-2_2 · Cited by 2
Metadata
- Authors
- Yang, B., Li, J., Haller, M. J., Schatz, D. A., & Rong, L.
- Affiliations
- University of Florida (US)
- University of Louisville (US)
- Corresponding author
- Rong, Libin
- Venue
- Frontiers in Endocrinology
- Publisher
- Frontiers Media SA
- Published
- 2022-12-21
- Volume
- 13
- Pages
- 1070979-1070979
- ISSN
- 1664-2392 (ISSN-L)
- PMC
- PMC9812520
- OpenAlex
- W4313484162
- Semantic Scholar
- fa855436d1118519cabc7a6625a4e6db91aa3e1a
- Cited by
- 6
- References
- 84
- Citations by year
- 2025: 3 · 2024: 2 · 2023: 1
- FWCI
- 0.36
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Endocrinology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Science Foundation (1950254)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Keywords
- secondary diabetes, diabetes progression, hyperthyroidism, glucocorticoid-induced diabetes, epinephrine, growth hormone, beta-cell failure, hyperglycemia, thyroid treatment
- MeSH terms
- Diabetes Mellitus, Type 2, Endocrine System Diseases, Endocrine System, Glucose, Humans, Hyperglycemia, Hyperthyroidism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The progression of secondary diabetes: A review of modeling studies. https://app.cochat.ai/papers/10.3389/fendo.2022.1070979
- The paper
- Yang, B., Li, J., Haller, M. J., Schatz, D. A., & Rong, L. (2022). The progression of secondary diabetes: A review of modeling studies. Frontiers in Endocrinology. https://doi.org/10.3389/fendo.2022.1070979
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.